Core Insights - Jinghua Pharmaceutical's stock increased by 0.25% on November 11, with a trading volume of 182 million yuan, indicating active market participation [1] - The company reported a financing buy of 12.04 million yuan and a financing repayment of 16.41 million yuan on the same day, resulting in a net financing outflow of 4.37 million yuan [1] - As of November 11, the total margin balance for Jinghua Pharmaceutical was 177 million yuan, representing 2.71% of its market capitalization [1] Financing and Margin Data - On November 11, the financing buy amounted to 12.04 million yuan, while the current financing balance stands at 177 million yuan, which is above the 70th percentile of the past year [1] - The short selling data shows no shares were sold or repaid on November 11, with a remaining short position of 2,000 shares and a short balance of 16,000 yuan, indicating a low level of short selling activity [1] Company Overview - Jinghua Pharmaceutical, established on January 3, 1994, and listed on February 3, 2010, is based in Nantong, Jiangsu Province [1] - The company's main business includes the research, production, and sales of traditional Chinese medicine preparations, chemical raw materials, and biopharmaceuticals [1] - The revenue composition is as follows: traditional Chinese medicine preparations (39.22%), chemical pharmaceutical intermediates (23.51%), chemical raw materials (20.79%), and Chinese medicinal materials (15.80%) [1] Financial Performance - For the period from January to September 2025, Jinghua Pharmaceutical achieved a revenue of 1.092 billion yuan, reflecting a year-on-year growth of 4.51% [2] - The net profit attributable to shareholders for the same period was 176 million yuan, showing a year-on-year increase of 7.39% [2] Shareholder and Dividend Information - Since its A-share listing, Jinghua Pharmaceutical has distributed a total of 533 million yuan in dividends, with 205 million yuan distributed over the past three years [3] - As of September 30, 2025, the number of shareholders decreased by 7.36% to 88,800, while the average number of circulating shares per person increased by 7.94% to 9,167 shares [2][3] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 6.8555 million shares, a decrease of 1.6727 million shares from the previous period [3]

Core Insights - On October 16, Jinghua Pharmaceutical's stock price remained unchanged at 0.00%, with a trading volume of 70.49 million yuan [1] - The company experienced a net financing outflow of 5.15 million yuan on the same day, with a total financing balance of 163 million yuan, representing 2.74% of its market capitalization [1] - As of June 30, 2025, Jinghua Pharmaceutical reported a revenue of 731 million yuan, a year-on-year increase of 1.54%, while its net profit attributable to shareholders decreased by 3.54% to 131 million yuan [2] Financing and Margin Trading - On October 16, the financing buy amount for Jinghua Pharmaceutical was 3.10 million yuan, with a total financing balance of 163 million yuan, which is below the 40th percentile of the past year [1] - The company had a margin trading balance of 67,400 yuan, with a short selling volume of 0 shares on October 16, indicating low activity in this area [1] Shareholder Structure - As of June 30, 2025, the number of shareholders for Jinghua Pharmaceutical was 95,900, a decrease of 5.29% from the previous period, while the average number of circulating shares per person increased by 5.58% to 8,492 shares [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 4.48 million shares to 8.53 million shares, while the Huatai-PineBridge CSI Traditional Chinese Medicine ETF reduced its holdings by 243,700 shares to 2.68 million shares [3]

Core Insights - The stock of Jinghua Pharmaceutical experienced a decline of 0.40% on September 17, with a trading volume of 64.30 million yuan [1] - As of September 17, the company had a total margin balance of 180 million yuan, with a financing net buy of -1.63 million yuan for the day [1][2] - The company reported a revenue of 731 million yuan for the first half of 2025, reflecting a year-on-year growth of 1.54%, while the net profit attributable to shareholders decreased by 3.54% to 131 million yuan [2][3] Financing and Margin Data - On September 17, Jinghua Pharmaceutical had a financing buy of 7.10 million yuan and a financing repayment of 7.26 million yuan, resulting in a net financing buy of -0.16 million yuan [1] - The current financing balance of 180 million yuan accounts for 2.94% of the circulating market value, which is above the 70th percentile of the past year [1] - The company had a margin balance of 28,500 yuan with a remaining short position of 3,800 shares, indicating a low level of short selling activity [1] Shareholder and Dividend Information - As of June 30, the number of shareholders for Jinghua Pharmaceutical was 95,900, a decrease of 5.29% from the previous period [2] - The company has distributed a total of 533 million yuan in dividends since its A-share listing, with 205 million yuan distributed in the last three years [3] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 4.48 million shares, and a new entry from the Traditional Chinese Medicine ETF [3]